Trevi Therapeutics, Inc. last reported quarterly results on Aug 6, 2026, for Q2 FY2026 (the quarter ended Jun 30, 2026): diluted EPS of -$0.11. It usually reports 17–44 days after a quarter ends. Based on that pattern, the next release is estimated for around Nov 12, 2026.
Results for Q3 FY2026, the quarter ending around Sep 30, 2026. Expected on a Thursday. Based on last year's release for the same quarter on Nov 13, 2025. This is an estimate, not a date the company has announced.
Release dates are when the company filed its earnings announcement with the SEC (Form 8-K, Item 2.02); select a date to open the filing. It usually reports 17–44 days after a quarter ends. Figures are USD in millions, except EPS. The colored percent is the change from the same quarter a year earlier. Until a quarter's 10-Q or 10-K figures reach the SEC's data, they come from the earnings press release, and are shown only when its year-ago numbers match the filed ones. A dash means the figure could not be confirmed yet.
| Released | Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|---|
|
Aug 6, 2026
37 days after quarter end
|
Q2 FY2026
ended Jun 30, 2026
|
—
|
-18
-44.7%
|
-0.11
-22.2%
|
|
Apr 17, 2026
17 days after quarter end
|
Q1 FY2026
ended Mar 31, 2026
|
—
|
-13
-27.6%
|
-0.09
+0.0%
|
|
Nov 13, 2025
44 days after quarter end
|
Q3 FY2025
ended Sep 30, 2025
|
—
|
-12
+10.9%
|
-0.08
+38.5%
|
|
Aug 7, 2025
38 days after quarter end
|
Q2 FY2025
ended Jun 30, 2025
|
—
|
-12
+0.4%
|
-0.09
+25.0%
|
|
May 8, 2025
38 days after quarter end
|
Q1 FY2025
ended Mar 31, 2025
|
—
|
-10
+5.2%
|
-0.09
+18.2%
|
|
Jan 8, 2025
8 days after quarter end
|
Q4 FY2024
ended Dec 31, 2024
|
—
|
-11
-46.0%
|
-0.11
-37.0%
|
|
Nov 6, 2024
37 days after quarter end
|
Q3 FY2024
ended Sep 30, 2024
|
—
|
-13
-72.0%
|
-0.13
-62.5%
|
|
Aug 8, 2024
39 days after quarter end
|
—
ended Jun 30, 2024
|
—
|
—
|
—
|
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- TRVI (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- New Haven, CT
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1563880
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.